Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TACE + cadonilimab + regorafenib in PD-(L)1-resistant unresectable hepatocellular carcinoma
ChiCTR2400085759Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jun 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab and regorafenib in hepatocellular carcinoma (HCC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: median progression-free survival. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
cadonilimabregorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400085759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085759.